Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Q: Evolocumab met the main goal of a late-stage trial titled RUTHERFORD-2 by lowering “bad” LDL cholesterol levels when tested against a placebo on 329 patients. Amgen, the world’s biggest biotechnology company, is testing evolocumab widely on a variety of subpopulations. The RUTHERFORD-2 study included patients with familial hypercholesterolemia, an inherited condition that causes high levels of “bad” LDL cholesterol starting at birth. Specifically, patients in the study had heterozygous familial hypercholesterolemia, which is one of the most common genetic disorders affecting about one out of every 300 to 500 people worldwide, according to Amgen. The company on Tuesday reported positive results from a fourth late-stage study of evolocumab, for which it plans to begin seeking approvals this year. The drug is intended for people who cannot tolerate widely used statins, or who are unable to get their LDL levels low enough despite using high potency statins, such as AstraZeneca’s Crestor. Amgen’s shares closed at $120.89 on the Nasdaq on Thursday.

A: Amgen's cholesterol fighter succeeds in fifth late-stage study.
****
Q: The story does a good job of describing the costs of angiopasty compared to a stress test. The story could have discussed out of pocket costs for patients. The story could have quantified the benefit of stress testing in its ability to avoid angiography and angioplasty associated with it. The story mentions missing cases of heart disease and difficulties of performing the test in older patients as potentional harms of stress testing, but there are other harms that the story should have mentioned. The story adequately describes the design of the current study and points out some important caveats inherent in a database-based study. The story does not exagerrate the seriousness or prevalence of stable heart disease. The story quotes multiple sources. The story mentions angiography as the alternative to stress testing. The story could have done more to describe the pros and cons of angiography compared to stress testing. Clearly stress tests are available. Clearly stress testing is not a new idea. Because the story quotes multiple experts, the reader can assume the story did not rely on a press release as the sole source of information.

A: More stress tests needed before angioplasties, study says
****
Q: The list price is 282,000 pounds ($369,000) per patient, given as a single intravenous infusion, but Novartis agreed to offer the therapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) at a confidential discounted price, the National Institute for Health and Care Excellence (NICE) said. NICE had turned down a previous proposal from Novartis in September, saying it exceeded the level considered an acceptable use of resources. “Today’s positive announcement regarding access to Kymriah treatment in England and Wales was secured as a result of our close working collaboration with NICE and NHS England, with all parties showing flexibility,” Novartis said. DLBCL patients eligible for Kymriah have life expectancies of just months, after failing previous treatments. Novartis expects Kymriah to eventually top $1 billion in annual sales, though the drug has started modestly with $76 million in 2018. Over 2019, the company expects to increase commercial and clinical capacity for Kymriah four-fold after buying more production facilities and deals with partners. The Swiss firm hopes expanding its treatment geography will narrow the sales gap with Gilead Sciences’ Yescarta, which reaped $183 million in the first nine months of 2018. Novartis already has NICE’s go-ahead for children and young people with aggressive acute lymphoblastic leukaemia (ALL) when other drugs have failed. The Basel-based company now has 26 treatment centers in the European Union and Kymriah is now commercially available to patients from 10 countries, it said. Kymriah belongs to a new class of treatments, like Yescarta, called CAR-T therapies where disease-fighting T cells are removed from a patient and genetically modified to better recognize and attack cancer. They are then re-infused into the same patient where they can circulate for years to seek out and fight the disease. Novartis is also working with the U.S. Food and Drug Administration to resolve a snag in which some batches of Kymriah did not meet commercial specifications, forcing the company to give it away for free to some patients. “We expect resolution ... soon,” a spokeswoman said.

A:
Novartis's cancer therapy wins UK backing after initial lymphoma snub.
****